LXRX Lexicon reports positive result from Phase 2 study

by Zagros on January 20, 2010

Briefing.com6:31 am January 20, 2010

Co announces it obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load. LX4211, dosed as a single agent, provided …

Tagged as: Accumulation, Diabetes, Diabetic Patients, Drug Candidate, Glucose Transporter, January 20, Lexicon, Molecule, Parameters, Patients With Type, Pharma, Phase 2, Rapid Improvements, Sodium, Transporter 2, Type 2 Diabetes, Type 2 Diabetes Mellitus, Type Diabetes

Leave a Comment

Previous post:

Next post: